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AbstrACt
Introduction In the UK, about a quarter of women 
give birth by caesarean section (CS) and are offered 
prophylactic broad-spectrum antibiotics to reduce the 
risk of maternal postpartum infection. In 2011, national 
guidance was changed from recommending antibiotics 
after the umbilical cord was cut to giving antibiotics 
prior to skin incision based on evidence that earlier 
administration reduces maternal infectious morbidity. 
Although antibiotics cross the placenta, there are no 
known short-term harms to the baby. This study aims to 
address the research gap on longer term impact of these 
antibiotics on child health.
Methods and analysis A controlled interrupted time 
series study will use anonymised mother-baby linked 
routine electronic health records for children born during 
2006–2018 recorded in UK primary care (The Health 
Improvement Network, THIN and Clinical Practice Research 
Datalink, CPRD) and secondary care (Hospital Episode 
Statistics, HES) databases. The primary outcomes of 
interest are asthma and eczema, two common allergy-
related diseases in childhood. In-utero exposure to 
antibiotics immediately prior to CS will be compared 
with no exposure when given after cord clamping. The 
risk of outcomes in children delivered by CS will also be 
compared with a control cohort delivered vaginally to 
account for time effects. We will use all available data from 
THIN, CPRD and HES with estimated power of 80% and 
90% to detect relative increase in risk of asthma of 16% 
and 18%, respectively at the 5% significance level.
Ethics and dissemination Ethical approval has been 
obtained from the University of Birmingham Ethical Review 
Committee with scientific approvals obtained from the 
independent scientific advisory committees from the 
Medicines and Healthcare products Regulatory Agency for 
CPRD and the data provider, IQVIA for THIN. The results 
will be published in peer-reviewed journals, presented at 
national and international conferences and disseminated 
to stakeholders.
IntroduCtIon
Births by caesarean section (CS) account for 
over 20% of births globally and are increasing.1 
Over one in four babies in the UK are born by 
CS.2–5 CS is a surgical procedure and women 
undergoing CS are at increased risk of devel-
oping infections after giving birth which can 
be prevented by prophylactic antibiotics. 
Before 2011, the national guidance advised 
administering intravenous prophylactic anti-
biotics for women undergoing CS after the 
baby’s cord had been clamped to prevent 
exposing the baby to antibiotics. In 2011, the 
guidance was changed to recommend giving 
antibiotics to women undergoing CS prior 
to skin incision. This was based on evidence 
strengths and limitations of this study
 ► A large sample size including mother-child linked 
data from two nationally representative primary 
healthcare databases and a secondary healthcare 
database.
 ► Investigation of a broad range of relevant child out-
comes including severity.
 ► Investigation of maternal outcomes using real world 
evidence to confirm findings reported in randomised 
controlled trials.
 ► Use of a comparison group of vaginally delivered 
children to effectively control for changes in diagno-
sis, recording and exposures over time.
 ► Timing of prophylactic antibiotic administration is 
not recorded in routine healthcare data; therefore, 
analysis is based on the estimated proportion of 
hospitals with the preincision antibiotic policy in 
each year during the study period.
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that earlier administration reduces maternal infectious 
morbidity.6 The current Cochrane review summarises 
data from 10 randomised trials (5041 women) which 
showed a near halving of risk of all postpartum maternal 
infection (43%, 95% CI 28% to 55%), endometritis (46%, 
CI 21% to 64%) and wound infection (41%, CI 19% to 
56%) compared with giving antibiotics after clamping the 
baby’s umbilical cord.7 Most postpartum maternal infec-
tions, however, are mild and respond well to treatment.8
Preoperative prophylactic antibiotics rapidly cross the 
placenta exposing babies to high dose broad spectrum 
antibiotics around the time of birth.9 Although no short-
term harms to the baby have been reported,6 intrapartum 
antibiotics have been shown to alter the gut microbiota of 
newborns.10 There is growing evidence that the composi-
tion of gut microbes in infants plays a role in their immune 
system development including response to different anti-
gens and inflammation and is associated with suscep-
tibility to asthma, allergies and other immune-related 
diseases later in life.11–18 There is a paucity of research 
regarding the longer term effect of preincision prophy-
lactic antibiotics for CS on child health.
Aim
The overall aim of this research study is to investigate 
whether the change in the guidance from recommending 
prophylactic antibiotics after cord clamping to preinci-
sion antibiotics has had any effect on the incidence of 
allergic and other related health conditions in children 
born by CS in the UK. This study will provide evidence on 
long-term impacts of CS preoperative prophylactic antibi-
otics to inform current guidance regarding the timing of 
administration of these antibiotics. It will either reinforce 
the current recommendation or, if negative impacts on 
child health are observed, will enable assessment of the 
magnitude of the risks against the benefits of reduced 
maternal morbidity.
objectives
The primary objective of the study is to investigate whether 
preincisional in-utero exposure to antibiotics immediately 
prior to birth (Intervention) compared with no preinci-
sional antibiotic exposure (Comparator) increases the 
risk of 1) asthma and 2) eczema (Outcomes) in children 
born by CS (Population). The relationship between anti-
biotic exposure and asthma and eczema severity (defined 
based on prescribing information and hospital admission 
data) will also be explored.
Secondary objectives:
1. Investigating the effect of preincision prophylactic an-
tibiotics in children born by CS on: a) other allergic 
and allergy-related diseases; b) autoimmune diseases; 
c) infections and inflammation; d) other immune sys-
tem-related conditions; e) neurodevelopmental con-
ditions; f) less specific measures of child health (colic 
and failure to thrive).
2. Investigating the effect of preincision prophylactic an-
tibiotics in children born by CS on health service utili-
sation (overall consultation frequency in primary care 
and hospital admissions).
3. Investigating if the effects of a reduction in postpartum 
maternal infectious morbidity shown in randomised 
controlled trials outside the UK can be replicated in 
the UK using routine healthcare data.
MEthods And AnAlysIs
study design
To address the primary objective and secondary objec-
tives 1 and 2, a controlled interrupted time series study 
will be undertaken using a cohort of women and their 
children born between 2006 and 2018 in the UK who 
are included in two routine primary care databases, The 
Health Improvement Network (THIN) or Clinical Prac-
tice Research Datalink (CPRD), and the secondary care 
HES database.
target population
Children born by CS and exposed, in utero, to antibiotics 
immediately prior to birth will be compared with children 
born by CS and not exposed, in utero, to antibiotics imme-
diately prior to birth. Children born vaginally during the 
same time period will be included as a control group.
Eligibility criteria
All liveborn children for whom the birth year is between 
2006 and 2018 will be included; the child and their moth-
er’s healthcare record can be linked in primary care 
(THIN or CPRD) or secondary care (HES) databases; 
the mode of delivery, CS or vaginal delivery (VD), can 
be identified based on recording in primary care (THIN, 
CPRD) and/or secondary care (HES).
Exclusion criteria
Children with missing delivery information will be 
excluded. In case of multiple births (eg, twins), one of 
the children will be randomly selected for inclusion to 
ensure independence of observations.
study outcomes
The primary outcomes for the study are the incidence 
of (1) asthma and (2) eczema. The main analysis for 
primary outcomes will be done separately in the primary 
care dataset and the secondary care (HES) dataset (the 
latter including only hospitals for which the year of anti-
biotic prescribing policy change is known).
Secondary outcomes are other allergic and allergy-re-
lated diseases, autoimmune diseases, infections and 
inflammation, other immune system-related conditions, 
neurodevelopmental conditions, less specific measures 
of child health, healthcare utilisation and maternal post-
partum infectious morbidity (table 1).
data sources
To maximise the sample size, we will combine two 
UK-wide primary care research databases, THIN and 
CPRD, containing anonymised patient records of over 
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Table 1 The list of secondary outcomes
Outcome
Corresponding 
secondary 
objective
Datasets analysed
Primary care
Secondary 
care
Health conditions and symptoms in children 1.
Other allergic and allergy-related conditions: 1.a
 ►  Food allergy/intolerance x
 ►  Allergic rhinitis and conjunctivitis x
 ►  >1 allergy related disease (asthma, eczema, food allergy/intolerance, allergic rhinitis 
and conjunctivitis)
x
 ►  Penicillin allergy* x
 ►  Anaphylaxis* x x
 ►  High risk of anaphylactic reaction (prescribing of automatic injection devices 
containing epinephrine)*
x
Autoimmune diseases: 1.b
 ►  Type 1 diabetes* x x
 ►  Coeliac disease* x x
 ►  Juvenile idiopathic arthritis* x x
 ►  Scleroderma/systemic sclerosis*† x x
 ►  Inflammatory myopathies*† x x
 ►  SLE*† x x
 ►  Autoimmune (idiopathic) ITP* x x
 ►  Juvenile pernicious (megaloblastic) anaemia* x x
 ►  Childhood vitiligo*† x
Infections and inflammation: 1 .c
 ►  Neonatal sepsis (early and late onset) x
 ►  Other sepsis* x
 ►  Wheeze x
 ►  Upper respiratory tract infections* x
 ►  Lower respiratory tract infections* x x
 ►  Bronchiolitis* x x
 ►  Gastroenteritis* x x
 ►  Inflammatory bowel disease† x x
 ►  Urinary tract infections* x x
 ►  Antibiotic prescribing* x
Other immune system-related conditions: 1.d
 ►  Necrotising enterocolitis x
 ►  Leukaemia*† x x
Neurodevelopmental conditions: 1.e
 ►  Cerebral palsy x
 ►  Autism spectrum disorder* x
 ►  ADHD* x
Less specific measures of child health: 1 .f
 ►  Colic* x
 ►  Failure to thrive* x
Healthcare utilisation in children 2.
 ►  Primary care consultations* x
 ►  Hospital admissions* x
Maternal outcomes (6 weeks postpartum) 3.
Continued
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Outcome
Corresponding 
secondary 
objective
Datasets analysed
Primary care
Secondary 
care
 ►  Composite infectious morbidity (wound infection, endometritis/endomyometritis, 
pelvic abscess, maternal sepsis, death attributed to infection)
x x
 ►  Endometritis/endomyometritis x x
 ►  Wound infection x x
 ►  Urinary tract infection/cystitis/pyelonephritis x x
 ►  Sepsis x x
 ►  Pelvic abscess x x
 ►  Maternal death (if infection related)*† x
 ►  Antibiotic prescribing* x
 ►  Length of hospital stay* x
*Exploratory outcome due to insufficient evidence base, including lack of longitudinal studies investigating the association between microbiota/early 
antibiotic exposure and outcome of interest;
†Tabulation if the outcome is very rare.
ADHD, attention deficit hyperactivity disorder; ITP, thrombocytopenic purpura; SLE, systemic lupus erythematosus.
Table 1 Continued
10% of the UK patient population.19 Both databases are 
broadly generalisable to the UK population in terms of 
demographics and medical condition prevalence.20 21 
There is overlap between the databases at general prac-
tice level, with THIN and CPRD containing 37% and 46% 
unique practices, respectively. The databases do not use 
the same identifiers for patients or practices, but the over-
lapping practices can be identified reliably using patient 
registration, demographic and medical record informa-
tion and the duplicates removed to create a combined 
THIN-CPRD dataset.19 22
Information on mothers and their children in the 
THIN-CPRD dataset can be linked using the family iden-
tification code, pregnancy codes, mother’s registered or 
estimated delivery date, child’s month of birth and gesta-
tional age at delivery. This is the optimal linkage method 
allowing identification of a large proportion of moth-
er-child pairs.23 24 In addition, in both THIN and CPRD a 
large proportion of patients (about 30% and 60%, respec-
tively) have linked hospital record data. Our estimates 
using THIN suggest that while the mode of delivery is 
accurately recorded in primary care (98% verified against 
hospital records), the recording is incomplete (the 
delivery mode is known for 55%–64% of children). The 
mode of delivery is well recorded in hospital records,3 
therefore where linked hospital data are available, this 
will increase the sample of children with known mode of 
delivery where this is missing in primary care data.
To allow us to investigate more severe outcomes of 
interest requiring hospital admissions which are better 
recorded in secondary care, we will also create a moth-
er-child linked database using anonymised Hospital 
Episode Statistics (HES) data collected for all NHS 
hospital admissions in England.25 This is a complex 
task requiring considerable expertise in record linkage, 
because in the UK there is no shared identifier to link 
maternal and child records in HES. It is, however, possible 
using deterministic and probabilistic linkage to attribute 
up to 98% of baby and mother secondary care records, 
as has been demonstrated in other large-scale studies of 
maternal and early life course research.26 27
We have a proposed linkage strategy which has already 
been validated by another recent study using matching 
algorithms based on HES data using organisation codes, 
admission dates, birth dates, general practice codes, sex, 
gestation and maternal age plus a number of other vari-
ables common to birth and maternity records. The data-
base remains nationally representative for the main birth 
characteristics (such as gestational age, birth weight, sex 
and maternal age).27 The final output of this process will 
be a linked HES data set in which details of birth events 
and subsequent admissions of the children associated 
with these events can be elucidated.
HES alone, however, cannot be used to identify timing 
of prophylactic antibiotic administration and prophy-
lactic antibiotics given. We will obtain the time point 
after which preincision antibiotic policy was introduced 
in each hospital from a national survey of maternity care 
providers in the UK. All maternity units undertaking CSs 
were included in the survey with a target response rate of 
85%.
The exposure and outcome measures in the healthcare 
databases will be defined using the Read clinical code 
classification system used in primary care, and Interna-
tional Statistical Classification of Diseases and Related 
Health Problems 10th Revision (ICD-10) used for clinical 
diagnoses, the Office of Population Censuses and Surveys 
Classification of Surgical Operations and Procedures 4th 
revision (OPCS) for procedures and Healthcare Resource 
Groups (HRG) codes used in HES.
Recording of some variables in healthcare data, such 
as breastfeeding, is incomplete; we will therefore also 
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investigate the trends in these variables by the mode of 
delivery using additional data sources such as the National 
Maternity Surveys.28
Methods
We will compare rates of diagnosis of asthma and other 
outcomes of interest over time in children born by CS, 
comparing outcomes according to whether each mother 
received preincisional antibiotics.
In the primary analysis, we will estimate a probability 
that each mother received preincisional antibiotics 
according to year of birth, based on national policy 
uptake rates in the year of delivery for primary care 
data. For secondary care data, we will use the response 
from each hospital indicating the year of local policy 
implementation.
The major threat to validity in this observational compar-
ison is not from case-mix confounders (indications for 
and incidence of CS have changed little over the study 
period); rather they relate to temporal changes in diag-
nosis and in the recording of outcomes and other expo-
sures which impact on the number of cases identified in 
routine data. Patterns of diagnosis of childhood asthma, 
for example, have changed over time, in part driven by 
the revisions in the national asthma management guide-
line and the potentially conflicting compliance and prev-
alence issues faced in meeting specific indicators of the 
Quality and Outcomes Framework (QOF) introduced in 
2004.29 30
An analysis reliant on adjustment for confounding 
factors is unlikely to succeed in controlling for these 
changes as it is unclear (1) what all the drivers of all 
these changes have been, (2) whether any covariates exist 
which accurately describe these changes without substan-
tial missing data and (3) challenges in specification of a 
functional form for the relationship between these covari-
ates and outcome.
In order to control for such temporal changes, we will 
use vaginally delivered (VD) children as a comparator, as 
this group will not have routinely received prophylactic 
antibiotics, but will have been subject to all the same 
temporal changes as those born by CS. Our study design 
will model the incidence of outcomes preintervention 
to predict the difference in disease incidence between 
babies born by CS (with antibiotics post cord-clamping) 
and VD (these are known to differ for some outcomes, 
such as asthma). From the period in which preinci-
sional antibiotics are introduced, we will compare the 
observed incidence rate in CS children with a counter-
factual incidence rate created by adding the VD-CS (post-
cord-clamping) difference to the observed incidence 
rate in VD children born postintervention. Subject to 
the assumption that the model of the difference between 
CS and VD rates is transferable across the time periods, 
differences between the observed and counterfactual CS 
event rates will be interpreted as likely to be caused by 
the change in practice.
Model validity
To assess model validity, we will explore changes in the 
case-mix of covariates over time in relation to delivery 
mode. Both maternal and child characteristics will be 
explored. The maternal characteristics considered will 
be: age at childbirth, ethnicity, parity, smoking status, 
body mass index before pregnancy, area deprivation 
coding, long-term allergy-related health conditions 
(asthma, eczema, allergic rhinitis and conjunctivitis), 
pregnancy and labour complications (premature rupture 
of membranes, postpartum haemorrhage, manual 
placental removal/retained products of conception) and 
antibiotic prescribing during pregnancy. The characteris-
tics of the child considered include: gestational age, sex, 
ethnicity, birth weight, breastfeeding status and antibiotic 
prescribing during the first 5 years.
Estimates of sample size and statistical power
To obtain estimates of statistical power and to estimate 
the impact of misclassification on estimates of increase in 
risk with prophylactic antibiotics before CS, we simulated 
the study (1) based on our estimates using the THIN 
database regarding the number of children with linked 
maternal data and asthma diagnosis rates in each year 
group between birth and 5 years of age, in line with previ-
ously published figures,31 and (2) using HES data based 
on estimates of children with linked maternal data and 
rates of children newly hospitalised for asthma assuming 
a readmission rate during the follow-up period of 50% 
based on HES statistics.25
In each simulation, we created a dataset for the whole 
study, with 13 birth cohorts from 2006 to 2018, and 
follow-up included across the first 5 years of life (curtailed 
at the end of 2018) (table 2). Each birth was classified by 
mode of delivery, and for those delivered by CS, whether 
antibiotics were given before skin incision, generated 
randomly using a binomial random number generator 
using an underlying probability of exposure to preinci-
sion antibiotics during that year of birth.
Outcome events were randomly simulated according to 
the year-age event rates using a binomial random number 
generator, with increased rates in all those delivered by 
CS, and increased further in those who received anti-
biotics before skin incision. A risk ratio of 1.2 was used 
for increased risk of asthma with CS32 and then further 
increases with risk ratios from RR=1.10 to RR=1.20 
(increasing in steps of 0.02) for the increase with antibi-
otics before skin incision rather than after cord-clamping.
Simulations were repeated 1000 times, and statistical 
power estimated by noting the proportion of simulations 
for which the lower limit of the 95% CI for the variable 
indicating whether antibiotics were given before skin inci-
sion was greater than a risk ratio of 1. We also recorded 
the estimates of the relative risk to assess attenuation bias 
created by misclassification.
The model which we fitted to analyse the simulation 
data included a trend term for the probability of receiving 
preincisional antibiotics with values 2006–2009=0, 
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Table 2 The number of births, years of follow-up and 
expected events in each simulation
THIN-CPRD 
database HES database
CS births 206 615 2 070 500
Postclamping antibiotics 111 508 1 115 670
Preincision antibiotics 95 107 954 830
VD births 570 774 5 973 100
Total births 777 389 8 043 600
CS person years of follow-up 792 265 8 661 832
Postclamping antibiotics 501 401 5 524 890
Preincision antibiotics 290 864 3 136 942
VD person years of follow-up 2 215 405 25 339 526
Total person years of follow-up 3 007 670 34 001 358
New events in children born by CS 7173 15 333
Postclamping antibiotics 5324 10 454
Preincision antibiotics 1849 4880
New events in children born by VD 20 378 44 906
Total events 27 551 60 240
Average event rate per 1000 person 
years
9.2 1.8
CPRD, Clinical Practice Research Datalink; CS, caesarean section; 
HES, Hospital Episode Statistics; THIN, The Health Improvement 
Network; VD, vaginal delivery.
2010=0.2, 2011=0.4, 2012=0.6, 2013=0.8, 2014–2018=1 
with a zero value for those delivery vaginally (in the final 
analysis, we will use probabilities for each year obtained 
from the survey).
For the primary care data, we have 80% power of 
detecting a 16% relative increase in risk of asthma and 
over 90% power of detecting an 18% relative increase in 
risk, and being able to estimate them with a maximum 
of 15% underestimation from misclassification. For the 
HES admission data, we have over 80% power to detect a 
10% relative increase in risk of asthma and 90% power to 
detect a 12% relative increase in risk with similar rates of 
underestimation due to misclassification.
The study will also be adequately powered to detect 
differences in the other primary outcome of interest 
(eczema) as incidence of clinician-diagnosed eczema is 
higher than asthma incidence in children in the UK.33–35
Analysis
The primary and secondary outcomes will be analysed 
using a Poisson regression model to estimate the rela-
tive risk of developing each outcome with preincision 
compared with postcord clamping antibiotics. We will 
assess for overdispersion and if high, consider other 
models, such as a negative binomial. Appropriate consid-
erations will be made to allow for the autocorrelation 
of data. We will look at the autocorrelation and partial 
autocorrelation plots to ensure any autocorrelation is 
accounted for. An adjustment for calendar time will be 
included in the model to allow for season effects. We will 
include terms for year, age and the interaction between 
them and mode of delivery (CS or vaginal). The key 
outcome parameter will be estimated by an additional 
term to identify those who receive preincision rather than 
postcord clamping antibiotics.
Rather than being described in dichotomous form, 
we will estimate the probability of preincision antibiotics 
using data from the national survey and known hospital 
policy. The estimated coefficient will provide an estimate 
of the change in policy, adjusting for misclassification.
Sensitivity analyses
Sensitivity to population changes:
 ► Analysis assessing the impact of the timing of the 
prophylactic antibiotic policy change, including 
comparison of analysis restricted to the years 2006–
2010 (before the change in the NICE guideline) 
compared with years where over 50% of hospitals had 
introduced the policy.
 ► Analysis of the primary outcomes in the full HES 
dataset (including data for the hospitals that do not 
respond to the survey and therefore preclude us 
linking information about prophylactic antibiotic 
policy at hospital level) using the estimated prob-
ability of introduction of preincisional antibiotics 
according to calendar year, to investigate the consist-
ency of findings.
 ► Analysis investigating the impact of the data recording 
quality (restricted to HES-linked records in THIN-
CPRD database as the most accurate source of records 
for the mode of delivery).
 ► Exploratory sensitivity analysis employing the 
discordant sibling approach (restricting the anal-
ysis to women who gave birth by CS more than 
once during the study period including before 
and after the change in the prophylactic antibiotic 
policy compared with women who gave birth by VD 
more than once during the study period) to control 
further for family-related genetic and environ-
mental factors.
Sensitivity to model changes:
 ► Analysis exploring whether the results are robust to 
the inclusion of a random effect for hospital.
Subgroup analyses:
 ► Exploratory subgroup analysis in HES mother-child 
linked database by prophylactic antibiotic type 
administered according to the individual hospital 
policies to investigate the potential impact of 
different antibiotics (cefuroxime alone, co-amox-
iclav alone, cefuroxime+metronidazole) on child 
outcomes.
 ► Exploratory subgroup analysis by the type of CS (it 
is hypothesised that children delivered by elective 
CS have a higher likelihood of asthma and related 
outcomes and are more likely to be exposed to 
in-utero antibiotics for longer than children born to 
women having an emergency CS).
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Patient and public involvement (PPI)
We have involved the public throughout the development 
of this study. This has reconfirmed the importance of the 
research question, particularly: the importance of assuring 
the baby’s health as a main priority when deciding on 
delivery options; that uncertainty as to whether antibiotics 
given around the time of birth have an impact on chil-
dren later in life should be resolved; that a robust study 
design is required to ensure the validity of the findings; 
a broad scope of important health and other outcomes 
which need to be considered; that the project needs to 
clearly communicate findings in terms of risks and bene-
fits; that the findings regarding prophylactic antibiotics 
for CS should form part of the wider discussion regarding 
risks and benefits of medications in pregnancy.
Two lay parent representatives are members of our 
Project Management Group and an independent parent 
representative is a member of the Project Steering 
Group. We also held two PPI discussion groups with 
mothers and mothers-to-be in two different locations in 
the West Midlands. These women were from a range of 
backgrounds, including women from black and minority 
ethnic communities, a group often under-represented 
in research. The focus of the sessions was on exploring 
what women wanted to know about this research and 
particularly which health conditions in relation to this 
study were important to them. PPI helped us to confirm 
that we should look at a wide range of outcomes and also 
consider the severity of outcomes. In addition, a wider 
public consultation took place via a survey, a link to which 
was sent to the Royal College of Obstetricians & Gynaecol-
ogists (RCOG) Women’s Voices Involvement Panel and 
British Intrapartum Care Society (BICS) which includes 
lay members. Based on findings from the PPI workshops 
and the survey, we have added neurodevelopmental 
conditions as secondary/exploratory study outcomes.
Clear communication and publicising of key find-
ings and messages are priorities of the study. Another 
PPI workshop is planned towards the end of the project 
to coproduce messages for dissemination via clinical 
networks, patient organisations and the media.
EthICs And dIssEMInAtIon
Ethical approval for this study has been provided by 
the Ethical Review Committee of the University of 
Birmingham (ERN_17–1675). The THIN database was 
approved by the NHS South-East Multi-Centre Research 
Ethics Committee.36 Approval for the use of THIN and 
HES-linked data in this study was provided by the Inde-
pendent Scientific Ethical Advisory Committee—Sci-
entific Review Committee panel of the data provider, 
IQVIA (18THIN047). The CPRD has ethics approval 
for observational research using anonymised data from 
a National Research Ethics Committee.37 The use of 
CPRD for this study has been approved by the Indepen-
dent Scientific Advisory Committee for MHRA Database 
Research (18_181AR2). The use of the HES database is 
exempt from NHS Research Ethics Committee approval 
because it involves the analysis of an existing dataset of 
non-identifiable data. Approval for the use of HES data 
was obtained as part of the standard NHS Digital data 
approval process.38 Health Research Authority (HRA) 
have confirmed that as the study involves linking anony-
mised patient data from established databases for our 
study only, HRA approval is not required.
The main aim of dissemination for this project is to 
ensure that parents-to-be and clinicians have clear infor-
mation about the benefits and risks of preincision prophy-
lactic antibiotics for CS based on the latest evidence to 
facilitate shared decision making. We will engage with 
the clinical and lay stakeholders throughout the project 
to benefit from the wider stakeholder input, to maximise 
the dissemination opportunities and to ensure that the 
research findings are communicated as widely as possible.
This will be achieved by: organising a further PPI work-
shop to produce a lay summary of the findings for wider 
dissemination, a dissemination event at the end of the 
project with lay, clinical stakeholders and professional 
organisations; dissemination to the clinical directors of 
maternity units; conference presentations, peer reviewed 
publications and dissemination via website and social 
media.
We will also maximise dissemination through: the 
Collaborations for Leadership in Applied Health 
Research and Care (CLAHRC) West Midlands (and its 
successor Applied Research Collaboration ARC) making 
use of their platform for dissemination; our strategic alli-
ance, Birmingham Health Partners (BHP), which aligns 
three NHS trusts in the West Midlands area; the West 
Midlands Academic Health Science Network (AHSN) 
whose responsibility it is to adopt, diffuse and disseminate 
innovation in the NHS.
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